Bio-Manguinhos, a branch of Brazil's top biomedical R&D centre, will develop and supply a combined measles and rubella vaccine for poor countries in Africa, Asia and Latin America. The aim is to export 30 million doses a year of the new double vaccine, to be sold at low cost.
Brazil's move follows those of other nations in the BRIC group of emerging markets, including India and China. The double MR vaccine is currently only produced by the Serum Institute of India.
Bio-Manguinhos also produces the MMR vaccine for use in immunisation campaigns within Brazil. However, the low prevalence of mumps in a number of developing countries and high cost of the triple vaccine means that hasn't been adopted by many of them.
Read more at Reuters >
If you want to know more about vaccines, and meet innovators, disruptors and influencers from across the vaccine research, development and technology landscape, find out about the World Vaccine Congress, 24-26 March 2014, Washington DC.